Similarly, MYO1B exon 23 (skipped in response to ESRP2) is both overall more skipped in prostate tumour versus normal, and more skipped in higher Gleason grade cancers (Figure 5—figure supplement 2E). Here, MYO1B is linked to prostate neoplasm.